Download View web only data 70KB

Cardiovascular manifestations of HIV (ht161463)
Jennifer E Ho, Priscilla Y Hsue
Web only references
1. Glynn M. Estimated HIV prevalence in the United States at the end of 2003.
National HIV Prevention Conference; June 12–15, 2005; Atlanta. Abstract T1B1101. 2005.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and
mortality among patients with advanced human immunodeficiency virus infection.
HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–60.
3. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease
with protease inhibitors. Lancet 1998;351:1328.
4. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of
HIV protease inhibitors. Lancet 1998;351:1959.
5. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction
with duration of protease inhibitor therapy in HIV-infected men. AIDS
2003;17:2479–86.
6. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected
individuals. J Acquir Immune Defic Syndr 2003;33:506–12.
7. Coplan PM, Nikas A, Japour A, et al. Incidence of myocardial infarction in
randomized clinical trials of protease inhibitor-based antiretroviral therapy: an
analysis of four different protease inhibitors. AIDS Res Hum Retroviruses
2003;19:449–55.
8. Iloeje UH, Yuan Y, L’Italien G, et al. Protease inhibitor exposure and increased
risk of cardiovascular disease in HIV-infected patients. HIV Med 2005;6:37–44.
9. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and
cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747–8.
10. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in
HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study.
Eur J Med Res 2000;5:329–33.
11. Klein D, Hurley LB, Quesenberry CP Jr, et al. Do protease inhibitors increase the
risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune
Defic Syndr 2002;30:471–7.
12. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected
and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis
2007;44:1625–31.
13. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates
and cardiovascular risk factors among patients with human immunodeficiency
virus disease. J Clin Endocrinol Metab 2007;92:2506–12.
14. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart
disease risk in HIV-infected men and women. Clin Infect Dis 2007;45:1074–81.
15. Barbaro G, Di Lorenzo G, Cirelli A, et al. An open-label, prospective,
observational study of the incidence of coronary artery disease in patients with
HIV infection receiving highly active antiretroviral therapy. Clin Ther
2003;25:2405–18.
16. DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of
myocardial infarction in HIV-infected patients. AIDS 2008.
17. Murphy R, Costagliola D. Increased cardiovascular risk in HIV infection: drugs,
virus and immunity. AIDS 2008;22:1625–7.
18. Matetzky S, Domingo M, Kar S, et al. Acute myocardial infarction in human
immunodeficiency virus-infected patients. Arch Intern Med 2003;163:457–60.
19. Mehta NJ, Khan IA. HIV-associated coronary artery disease. Angiology
2003;54:269–75.
20. Ambrose JA, Gould RB, Kurian DC, et al. Frequency of and outcome of acute
coronary syndromes in patients with human immunodeficiency virus infection.
Am J Cardiol 2003;92:301–3.
21. Varriale P, Saravi G, Hernandez E, et al. Acute myocardial infarction in patients
infected with human immunodeficiency virus. Am Heart J 2004;147:55–9.
22. Trachiotis GD, Alexander EP, Benator D, et al. Cardiac surgery in patients
infected with the human immunodeficiency virus. Ann Thorac Surg
2003;76:1114–8; discussion 8.
23. Horberg MA, Hurley LB, Klein DB, et al. Surgical outcomes in human
immunodeficiency virus-infected patients in the era of highly active antiretroviral
therapy. Arch Surg 2006;141:1238–45.
24. Tabib A, Leroux C, Mornex JF, et al. Accelerated coronary atherosclerosis and
arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron
Artery Dis 2000;11:41–6.
25. Micheletti RG, Fishbein GA, Fishbein MC, et al. Coronary atherosclerotic lesions
in human immunodeficiency virus-infected patients: a histopathologic study.
Cardiovasc Pathol 2008.
26. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J
Med 2005;352:1685–95.
27. Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic
endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993;150:4601–9.
28. Lichtenstein KA. HIV Outpatient Study Cohort (HOPS): Low CD4 Associated
with New Cardiovascular Events. Abstract, International AIDS Conference on
HIV Pathogenesis and Treatment, Mexico: 2008.
29. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases
following initial treatment for HIV infection. AIDS 2008;22:841–8.
30. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major
atherosclerosis risk factor in HIV-infected women and men. AIDS 2008;22:1615–
24.
31. Blum A, Hadas V, Burke M, et al. Viral load of the human immunodeficiency
virus could be an independent risk factor for endothelial dysfunction. Clinical
cardiology 2005;28:149–53.
32. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected
persons. Clin Infect Dis 2006;42:1325–32.
33. Seigneur M, Constans J, Blann A, et al. Soluble adhesion molecules and
endothelial cell damage in HIV infected patients. Thromb Haemost 1997;77:646–
9.
34. Melendez MM, McNurlan MA, Mynarcik DC, et al. Endothelial adhesion
molecules are associated with inflammation in subjects with HIV disease. Clin
Infect Dis 2008;46:775–80.
35. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in
HIV patients is associated with increased cytomegalovirus-specific T-cell
responses. AIDS 2006;20:2275–83.
36. Kuller L, SS G. Elevated Levels of Interleukin-6 and D-dimer Are Associated
with an INcreased Risk of Death in Patients with HIV. Abstract #139, presented at
the 15th Conference on Retroviruses and Opportunistic Infections, February 2008,
Boston, MA 2008.
37. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6
and mortality in patients with unstable coronary artery disease: effects of an early
invasive or noninvasive strategy. JAMA 2001;286:2107–13.
38. Feingold KR, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired
immunodeficiency syndrome is associated with an increased prevalence of low
density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993;76:1423–7.
39. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on
serum lipids in men. JAMA 2003;289:2978–82.
40. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events
associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet
2001;358:1322–7.
41. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection
receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical
course and management. Int J Antimicrob Agents 2003;22:89–99.
42. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and postheparin lipase activities in normal subjects. AIDS 2000;14:51–7.
43. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48weeks
(AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir
at three doses in combination with didanosine and stavudine in antiretroviral-naive
subjects. J Acquir Immune Defic Syndr 2003;32:18–29.
44. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of
atazanavir and efavirenz, each administered in combination with zidovudine plus
lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis
2006;42:273–80.
45. Jerico C, Knobel H, Montero M, et al. Metabolic syndrome among HIV-infected
patients: prevalence, characteristics, and related factors. Diabetes Care
2005;28:132–7.
46. Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease
and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV
infection. AIDS 2007;21:2445–53.
47. Savès M, Chêne G, Ducimetière P, et al. Risk factors for coronary heart disease in
patients treated for human immunodeficiency virus infection compared with the
general population. Clin Infect Dis 2003;37:292–8.
48. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course
of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and
diabetes mellitus: a cohort study. Lancet 1999;353:2093–9.
49. O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media
thickness as a risk factor for myocardial infarction and stroke in older adults.
Cardiovascular Health Study Collaborative Research Group. N Engl J Med
1999;340:14–22.
50. Kablak-Ziembicka A, Tracz W, Przewlocki T, et al. Association of increased
carotid intima-media thickness with the extent of coronary artery disease. Heart
2004;90:1286–90.
51. Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV infection and
highly active antiretroviral therapy are independent risk factors for early carotid
atherosclerosis. Atherosclerosis 2008;196:720–6.
52. Currier JS, Kendall MA, Henry WK, et al. Progression of carotid artery intimamedia thickening in HIV-infected and uninfected adults. AIDS 2007;21:1137–45.
53. de Saint Martin L, Vandhuick O, Guillo P, et al. Premature atherosclerosis in HIV
positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA
study). Atherosclerosis 2006;185:361–7.
54. Jerico C, Knobel H, Calvo N, et al. Subclinical carotid atherosclerosis in HIVinfected patients: role of combination antiretroviral therapy. Stroke 2006;37:812–
7.
55. Maggi P, Perilli F, Lillo A, et al. Rapid progression of carotid lesions in HAARTtreated HIV-1 patients. Atherosclerosis 2007;192:407–12.
56. Mangili A, Gerrior J, Tang AM, et al. Risk of cardiovascular disease in a cohort
of HIV-infected adults: a study using carotid intima-media thickness and coronary
artery calcium score. Clin Infect Dis 2006;43:1482–9.
57. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness
and HIV infection: traditional risk factors overshadow impact of protease inhibitor
exposure. AIDS 2005;19:927–33.
58. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected
individuals—focus on protease inhibitor therapy. AIDS 2001;15:329–34.
59. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in
HIV-1-infected patients treated with protease inhibitors. AIDS 2000;14:F123–8.
60. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis.
Circulation 2004;109:III27–32.
61. Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk?
Circulation 2002;106:640–2.
62. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound
assessment of endothelial-dependent flow-mediated vasodilation of the brachial
artery: a report of the International Brachial Artery Reactivity Task Force. J Am
Coll Cardiol 2002;39:257–65.
63. Charakida M, Donald AE, Green H, et al. Early structural and functional changes
of the vasculature in HIV-infected children: impact of disease and antiretroviral
therapy. Circulation 2005;112:103–9.
64. Blanco JJ, García IS, Cerezo JG, et al. Endothelial function in HIV-infected
patients with low or mild cardiovascular risk. J Antimicrob Chemother
2006;58:133–9.
65. Grubb JR, Dejam A, Voell J, et al. Lopinavir-ritonavir: effects on endothelial cell
function in healthy subjects. J Infect Dis 2006;193:1516–9.
66. Dubé MP, Gorski JC, Shen C. Severe Impairment of Endothelial Function with
the HIV-1 Protease Inhibitor Indinavir is not Mediated by Insulin Resistance in
Healthy Subjects. Cardiovasc Toxicol 2008;8:15–22.
67. Shankar SS, Dubé MP, Gorski JC, et al. Indinavir impairs endothelial function in
healthy HIV-negative men. Am Heart J 2005;150:933.
68. Jiang B, Hebert VY, Zavecz JH, et al. Antiretrovirals induce direct endothelial
dysfunction in vivo. J Acquir Immune Defic Syndr 2006;42:391–5.
69. Arad Y, Spadaro LA, Goodman K, et al. Prediction of coronary events with
electron beam computed tomography. J Am Coll Cardiol 2000;36:1253–60.
70. Kingsley LA, Cuervo-Rojas J, Munoz A, et al. Subclinical coronary
atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS
Cohort Study. AIDS 2008;22:1589–99.
71. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed
risk of AIDS-related mortality among individuals enrolling into care with CD4+
counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179–
87.
72. Executive Summary of The Third Report of The National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High
Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–
97.
73. Hare CB, Vu MP, Grunfeld C, et al. Simvastatin-nelfinavir interaction implicated
in rhabdomyolysis and death. Clin Infect Dis 2002;35:e111–2.
74. van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and
pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in
HIV-infected patients. Antivir Ther (Lond) 2007;12:1127–32.
75. Busti AJ, Bain AM, Hall RG, et al. Effects of Atazanavir/Ritonavir or
Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin. J Cardiovasc
Pharmacol 2008;51:605–10.
76. Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to
maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health
Dis 2007;6:15.
77. Wohl DA, Waters D, Simpson RJ Jr, et al. Ezetimibe alone reduces low-density
lipoprotein cholesterol in HIV-infected patients receiving combination
antiretroviral therapy. Clin Infect Dis 2008;47:1105–8.
78. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the
management of persons infected with human immunodeficiency virus:
recommendations of the HIV Medicine Association of the Infectious Diseases
Society of America. Clin Infect Dis 2004;39:609–29.
79. Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV
infection. Chest 1991:1268–71.
80. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial
hypertension: trends in the HAART era. AIDS 2008;22(Suppl 3):S35–40.
81. Hsue PY, Deeks SG, Farah HH, et al. Role of HIV and human herpesvirus-8
infection in pulmonary arterial hypertension. AIDS 2008;22:825–33.
82. Grubb JR, Moorman AC, Baker RK, et al. The changing spectrum of pulmonary
disease in patients with HIV infection on antiretroviral therapy. AIDS
2006;20:1095–107.
83. Mehta NJ, Khan IA, Mehta RN, et al. HIV-Related pulmonary hypertension:
analytic review of 131 cases. Chest 2000:1133–41.
84. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor
expression in primary pulmonary hypertension: comparison of HIV seropositive
and HIV seronegative patients. Eur Respir J 1998;11:554–9.
85. Pellicelli AM, Palmieri F, Cicalini S, et al. Pathogenesis of HIV-related
pulmonary hypertension. Annals of the New York Academy of Sciences
2001;946:82–94.
86. Opravil M, Pechère M, Speich R, et al. HIV-associated primary pulmonary
hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit
Care Med 1997;155:990–5.
87. Morse JH, Barst RJ, Itescu S, et al. Primary pulmonary hypertension in HIV
infection: an outcome determined by particular HLA class II alleles. Am J Respir
Crit Care Med 1996;153:1299–301.
88. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human
immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir
Crit Care Med 2004:1212–7.
89. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human
immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir
Crit Care Med 2003;167:1433–9.
90. Barbaro G. HIV-associated cardiomyopathy etiopathogenesis and clinical aspects.
Herz 2005;30:486–92.
91. Khunnawat C, Mukerji S, Havlichek D, et al. Cardiovascular manifestations in
human immunodeficiency virus-infected patients. Am J Cardiol 2008;102:635–42.
92. Herskowitz A, Wu TC, Willoughby SB, et al. Myocarditis and cardiotropic viral
infection associated with severe left ventricular dysfunction in late-stage infection
with human immunodeficiency virus. J Am Coll Cardiol 1994;24:1025–32.
93. Lipshultz SE, Orav EJ, Sanders SP, et al. Immunoglobulins and left ventricular
structure and function in pediatric HIV infection. Circulation 1995;92:2220–5.
94. Fisher SD, Easley KA, Orav EJ, et al. Mild dilated cardiomyopathy and increased
left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter
Study. Am Heart J 2005;150:439–47.
95. Neumann T, Esser S, Potthoff A, et al. Prevalence and natural history of heart
failure in outpatient HIV-infected subjects: rationale and design of the HIVHEART study. Eur J Med Res 2007;12:243–8.
96. Levy RM, Bredesen DE. Central nervous system dysfunction in acquired
immunodeficiency syndrome. J Acquir Immune Defic Syndr 1988;1:41–64.
97. Evers S, Nabavi D, Rahmann A, et al. Ischaemic cerebrovascular events in HIV
infection: a cohort study. Cerebrovasc Dis 2003;15:199–205.
98. d’Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in
HIV-infected persons. AIDS 2004;18:1811–7.
99. Velasquez EM, Glancy DL. Cardiovascular disease in patients infected with the
human immunodeficiency virus. J La State Med Soc 2003;155:314–24.
100. Heidenreich PA, Eisenberg MJ, Kee LL, et al. Pericardial effusion in AIDS.
Incidence and survival. Circulation 1995;92:3229–34.
101. Zareba KM, Lipshultz SE. Cardiovascular Complications in Patients with HIV
Infection. Curr Infect Dis Rep 2003;5:513–20.
102. EuroHIV. HIV/AIDS surveillance in Europe: mid-year report 2005, No 72.
August. Saint-Maurice, Institut de Veille Sanitaire. Available at
http://www.eurohiv.org. 2006.